Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Neoplasms 2Synovial Cyst 1Spondylosis 1Spondylolisthesis 1Spinal Stenosis 1Radiculopathy 1Pilonidal Sinus 1Pain, Postoperative 1Neoplasms, Second Primary 1Musculoskeletal Diseases 1Malignant Neoplasms of Male Genital Organs 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hot Flashes 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × Clonidine × Clear all
NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Wake Forest University Health Sciences

Phase 3 Recruiting
170 enrolled
Genitourinary

Agnosia, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡